ClinicalTrials.gg
CompletedNCT02375906HDINUpdated Jun 2, 2022

The Hepatitis Delta International Network

An observational study in Hepatitis D, sponsored by HepNet Study House, German Liverfoundation. Completed at 18 sites in 12 countries. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by HepNet Study House, German Liverfoundation · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Hepatitis D with a site in Germany — 3 open to participants now, 9 under way, 4 of them phase 3. Hepatitis D · Germany.

Started
2013
the only one that year
Observational
4 of 13
2 open now
Registered
2nd of 13
by date
Lead sponsor
2 of 13
HepNet Study House, German Liverfoundation

Among the 13 studies in Hepatitis D with a site in Germany, this one is the only one that started in 2013, is one of 4 observational ones, and was the 2nd registered.

Hepatitis D

63 studies on the registry are indexed under Hepatitis D; 21 are open to participants now.

Browse Hepatitis D studies →

Open to participants now

3 of the 13 studies in Hepatitis D with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 14 Hepatitis D studies recruiting now, 9 (64%) set no upper age limit and 1 (7%) stops at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis D with a site in Germany, or all of them as a file.
02

Study summary

Hepatitis delta is a major health problem, not only because of the severity of the disease, but also due to the lack of effective antiviral treatment. To improve the current therapeutic options, a better understanding of the pathophysiology is essential. Reliable research in this direction is only possible with large patient study groups. However, given the geographic distribution of hepatitis delta, larger patient cohorts would only be possible through multicenter collaboration.

Read the detailed description

The hepatitis international network cohort is a multicenter, observational study that will build up a research registry of HDV patients all over the world.

The aims of this project are:

i. Collect clinical information from hepatitis delta patients from multiple centers distributed worldwide in order to build up a large database that will enable and facilitate further research on chronic hepatitis delta.

ii. To better inform patients about their viral infection, present status and evolution of liver disease throughout time. To give them the tools needed to inform other peers and medical professionals about the significance and consequences of a chronic hepatitis delta infection.

iii. To allow the participating physicians to track course of the disease, therapies, signs and symptoms of the hepatitis delta patients included by their center.

03

Conditions studied

  • Hepatitis D

Browse trials for

Keywords

  • HDV, hepatitis delta
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with chronic hepatitis delta will be screened regardless of HDV or HBV genotype

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive HBs antigen and antiHDV for longer than 6 months.

Exclusion criteria

Exclusion Criteria:

Absence of any cause of relevant liver disease other than HDV (i.e. hemochromatosis, hepatitis, alcoholic or toxic liver disease, etc.)

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
2,000 participants (actual)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Proportion of chronic hepatitis B patients with chronic hepatitis D infection worldwide

    Time frame: 10 years

Secondary outcomes

  1. HDV-RNA HBsAg

    Time frame: 10 years

  2. HBV-DNA

    Time frame: 10 years

  3. Proportion of treated chronic hepatitis B patients with chronic hepatitis D infection worldwide

    Time frame: 10 years

07

Study locations

18 sites
  • Medical University of Vienna; Internal Med.III
    Vienna, Austria
  • Antwerpen University Hospital
    Edegem, Belgium
  • Centro de Pesquisa em Medicina Tropical
    Rondonia, Brazil
  • Medical Center Mrcheveli
    Tiflis, Georgia
  • Medizinisches Infektiologiezentrum
    Berlin, 10439, Germany
  • Medizinische Klinik I Charite- Campus Benjamin Franklin
    Berlin, Germany
  • Universitätsklinikum Giessen-Marburg
    Gießen, Germany
  • Medizinische Hochschule Hannover
    Hannover, Germany
  • Dep.of Medicine University of Thessalony
    Larissa, Greece
  • Centro di ricerca per lo studio della Epatiti
    Bologna, Italy
  • Gastroenterology Casa Sollievo della Sofferenza Hospital
    San Giovanni Rotondo, Italy
  • A.O.U. Citta della Salute e della Scienza di Torino
    Torino, Italy
  • The University of Medicine "Nicolae Testimitanu"
    Chisinau, Moldova, Republic of
  • Dept.of Medicine Aga Khan University
    Karachi, Pakistan
  • Liverstomach Clinic
    Karachi, Pakistan
  • Clinical Hospital of Infectious Disease "dr. Victor Babes"
    Bucharest, Romania
  • Hospital Vall d´Hebron
    Barcelona, Spain
  • Vietnamese-German Center for Medical Research
    Hanoi, Vietnam
08

References and documents

Publications

  • Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, Wedemeyer H, Hardtke S; Hepatitis Delta International Network. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN). Liver Int. 2018 May;38(5):842-850. doi: 10.1111/liv.13604. Epub 2017 Oct 26. PubMed 28963781 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2013 to primary completion in May 2022, 102 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2015
First posted
Mar 3, 2015
StartActual
Nov 2013
Primary completionActual
May 31, 2022
CompletionActual
May 31, 2022
Last update
Jun 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02375906
Lead sponsor
HepNet Study House, German Liverfoundation
Collaborators
German Center for Infection Research, Hannover Medical School
Responsible party
Sponsor
First posted
Mar 3, 2015
Start date
Nov 2013
Primary completion
May 31, 2022
Completion
May 31, 2022
Last update
Jun 2, 2022

Study contacts

Michael P Manns, Prof. Dr.
principal investigator · Hannover Medical School

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion